66 results about "Cell brain" patented technology

The invention relates to the technical field of medical image processing, and discloses an adversarial generative network model for three-dimensional reconstruction of a brain cell-level vascular network. The model comprises a three-dimensional blood vessel feature extraction module, a dynamic attention generator, a multi-scale discriminator and the like. Characteristics are obtained through multi-modal medical image data (magnetic resonance angiography and confocal microscope scanning data), and high-precision vascular network three-dimensional reconstruction is realized by utilizing cooperative work of all the modules. The dynamic attention generator calculates the topological connection probability of the vascular branches, and the multi-scale discriminator globally and locally evaluates the reconstruction result. Meanwhile, model training is optimized through an adversarial training controller, and the blood vessel network is perfected through a capillary network completion module. According to the method, the advantages of multi-modal data are effectively fused, the reconstruction precision is improved, and powerful support is provided for research and diagnosis of brain vascular diseases.

The invention belongs to the technical field of bioengineering, and discloses a sunflower seed peptide for regulating metabolism of brain cells, the sunflower seed peptide has a biological sequence of Arg His Ala Lys Thr Pro Ser Asn Lys, and a preparation method of the sunflower seed peptide for regulating metabolism of brain cells comprises the following specific steps: S1, raw material pretreatment; s2, peeling and crushing; s3, protein extraction; s4, performing enzymolysis treatment; s5, performing enzyme deactivation treatment; s6, filtering and purifying; s7, concentrating and drying; and S8, quality detection and packaging. The sunflower seed protein is directionally decomposed into the active peptide fragment by precisely regulating and controlling compound protease and enzymolysis conditions, the active peptide fragment can be compatible with a brain cell specific receptor and penetrate through a blood brain barrier, and cell experiments and animal models prove that the peptide fragment can activate a mitochondrial respiratory chain complex, so that the mitochondrial membrane potential is increased by more than 30%, and the mitochondrial membrane potential is increased by more than 30%. Meanwhile, the activity of neurotransmitter synthetase can be enhanced, the brain health is protected, and tests further prove that the sunflower seed peptide also has the function of regulating the metabolism of brain cells.

The invention provides brain cell specific targeting delivery based on exosome, and the exosome secreted by 293T cells is used for engineering transformation, so that the capabilities of penetrating BBB and specifically targeting neurons are achieved. According to the present invention, the L1CAM is loaded on the exosome, the exosome is obtained by transfecting a 293T cell of a Lamp2b-L1CAM PCDH-HygroHA plasmid through a 293T-Lamp2b-L1CAM cell line, and the BBB cell-penetrating peptide 4F-T7 and the neuronal targeting protein L1CAM are loaded on the surface of the exosome so as to treat the neurodegenerative diseases such as the Alzheimer's disease and the Parkinson's disease.

Provided herein are methods of expressing syntaxin-binding protein 1 (STXBP1) in a neuron. Also provided herein is a modified adeno-associated virus (AAV) encoding a STXBP1 under the control of a promoter operable in a brain cell or neuronal cell.

Provided herein are methods of detecting an aggression level of a glioblastoma in a subject. In some embodiments, the methods include imaging the subject having the glioblastoma using a CEST MRI technique in the absence of introducing an exogenous MRI contrast agent into the subject to produce a test MR image of the subject. In some embodiments, the methods also include identifying an overexpression level of mannose in and / or on surfaces of unlabeled cancer stem cells of the glioblastoma of the subject in the test MR image relative to an identified expression level of mannose in and / or on surfaces of brain cells in a control MR image, wherein a high aggression level is indicated when the overexpression level comprises at least about a 1.8-fold difference and wherein a low aggression level is indicated when the overexpression level comprises less than about a 1.8-fold difference. Related aspects are also provided.

The present invention relates to the field of biotechnology. The present invention provides a grass carp brain cell line sensitive to grass carp reovirus type II, which was deposited in the China Center for Type Culture Collection on October 19, 2024, with a deposit number of CCTCC NO: C2024101. The grass carp brain cell line constructed by the present invention shows remarkable stability and successfully achieved 60 stable passages. When inoculated with GCRV‑II, an atypical cytopathic effect can be exhibited. In addition, the grass carp brain cell line has the ability to efficiently replicate GCRV‑II, and even after three generations of blind transmission, the generated cytotoxin can still cause grass carp to become ill and die. Therefore, the present invention has laid a solid foundation for in-depth exploration of the pathogenic mechanism of GCRV‑II, vaccine development, and antiviral drug screening, which will help promote further progress in related research and provide a key cell model and research basis for the formulation of grass carp reovirus-related research and prevention and control strategies.

The present invention relates to a composition for treating or preventing neurodevelopmental disorders, particularly autism spectrum disorder, by selectively activating brain-resident regulatory T cells (Tregs). The present composition comprises IL-2 or an IL-2 gene (AAV-GFAP-IL-2) as an active ingredient, and induces Treg proliferation in the brain to alleviate neuroinflammation and improve behavioral defects.

Provided herein are methods of detecting an aggression level of a glioblastoma in a subject. In some embodiments, the methods include imaging the subject having the glioblastoma using a CEST MRI technique in the absence of introducing an exogenous MRI contrast agent into the subject to produce a test MR image of the subject. In some embodiments, the methods also include identifying an overexpression level of mannose in and / or on surfaces of unlabeled cancer stem cells of the glioblastoma of the subject in the test MR image relative to an identified expression level of mannose in and / or on surfaces of brain cells in a control MR image, wherein a high aggression level is indicated when the overexpression level comprises at least about a 1.8-fold difference and wherein a low aggression level is indicated when the overexpression level comprises less than about a 1.8-fold difference. Related aspects are also provided.

The invention provides a construction method and device for a brain structure connection atlas, and the method comprises the steps: obtaining a three-dimensional fluorescence microscopic image of brain cells; calculating a response function according to the gradient distribution of the unidirectional fiber groups; according to the gradient weighted sampling data and the response function of each voxel v in the three-dimensional fluorescence microscopic image, constructing a brain structure connection map; the gradient weighted sampling data at each voxel v represents discrete sampling in each direction of the gradient spherical continuous distribution function within a predetermined range near each voxel v. According to the method, the three-dimensional orientation distribution of the white matter nerve fibers of the brain can be obtained through analysis, then the three-dimensional brain structure connection diagram is constructed according to the fiber orientation distribution, and the method has the advantages of being high in speed, high in precision and capable of achieving three-dimensional analysis.

The application discloses application of a swertianol derivative in preparation of a glioma treatment drug and belongs to the technical field of medicines. The application finds that the compound has significant inhibitory activity on SF126, T98G, A172, U-87 MG, U251 and various glioma cell lines, and the activity is better than that of temozolomide, a commonly used clinical anti-glioma drug, and the compound has lower toxicity to normal brain cells. The application further provides a preparation method of the compound and a pharmaceutical composition containing the compound, and the pharmaceutical composition can be prepared into injection, tablets and various dosage forms. The application provides a new effective drug selection for the treatment of glioma, has a mature preparation process, various drug dosage forms and a wide clinical application prospect.

Fibrinogen-coated Albumin Nanospheres (FAS) has shown that it can mobilize bone marrow cells into the blood which then go to injured soft and hard tissues to achieve accelerated repair. It is hypothesize that (a) brain injuries caused by low-dose irradiation under simulated microgravity can be mitigated by the administration of FAS; and (b) the mechanism is from acceleration of neo-vascularization, proven by lineage study of GFP-labeled bone marrow cells implanted into compatible non-GFP animals before injury, which regenerate into functional GFP-brain cells after FAS treatment.

The present disclosure relates to LNP formulations useful for uptake in the CNS or brain, for example, in some cases wherein the LNP is conjugated to an antigen binding fragment of an anti-transferrin receptor antibody. The present disclosure also relates to methods of delivering lipid nanoparticles (LNPs) systemically, for uptake in vivo in the central nervous system (CNS), such as to brain cells, and methods for assessment of the extent of uptake in CNS cells, such as brain cells. In some cases, methods allow for high throughput screening of multiple different LNPs in parallel.

The invention discloses application of carabrone derivatives in preparation of glioma drugs, and belongs to the technical field of medicines. It is found for the first time that the compound has remarkable inhibitory activity on multiple glioma cell lines such as SF126, T98G, A172, U-87 MG and U251, the activity of the compound is superior to that of temozolomide which is a clinically common anti-glioma drug, and meanwhile the compound is low in toxicity to normal brain cells. The invention also provides a preparation method of the compound and a pharmaceutical composition containing the compound. The pharmaceutical composition can be prepared into various dosage forms such as injections, tablets and the like. The invention provides a new effective drug choice for the treatment of glioma, and has the advantages of mature preparation process, various dosage forms and wide clinical application prospect.

The invention belongs to the technical field of coffee products, and particularly relates to a coffee composition for relieving depressive symptoms and a preparation method thereof. 25-30 parts of coffee beans, 6-10 parts of fructus rosae laevigatae, 6-10 parts of semen boitae, 8-12 parts of cortex albiziae and 1-3 parts of seaweed are limited, and different raw materials are extracted, decocted or subjected to enzymolysis, so that separation and retention of active ingredients of the raw materials are facilitated, and the active ingredients in fructus rosae laevigatae, semen boitae, cortex albiziae and seaweed have a protection effect on brain cells; the traditional Chinese medicine composition is beneficial to recovering the balance of a nervous system, relieving the inflammatory response in the brain, reducing the generation of oxygen free radicals, reducing the activity of xanthine oxidase in the cerebral cortex and improving the symptom of depression; and chlorogenic acid, nicotinic acid and the like in coffee can generate positive influence on depression symptoms. Therefore, the coffee composition provided by the invention can be used for relieving depression symptoms and provides a basis for adjuvant therapy of depression.

The invention discloses a composition for enhancing memory and improving cognitive function and application. The composition disclosed by the invention comprises acanthopanax, ginseng, Chinese wolfberry fruits, gastrodia elata, spina date seeds, poria cocos, Chinese yams, lotus seeds, gordon euryale seeds, mulberries, longan pulp, fresh ginger, walnut powder, egg protein powder, blueberry powder, raspberry powder, pumpkin seed powder, oat powder, spirulina powder, dark chocolate powder, a vitamin B group compound, gamma-aminobutyric acid, galactooligosaccharide and citric acid. According to the invention, a multi-channel and multi-target collaborative network is constructed by taking acanthopanax senticosus as a core, through multiple channels such as nerve regeneration, energy metabolism, oxidative stress, signal transduction, endocrine regulation and the like, different nodes such as neurons, neuroglial cells, cerebrovascular endothelium and the like are targeted, the overall optimization of the memory function is realized on the system level, and the memory function is optimized. The core idea of systematic biology of overall regulation and control is reflected, and the composition prepared from the composition has the effects of improving memory, learning ability and cognitive ability.

The present invention relates to use of PAK4 and CRTC1 or the treatment or diagnosis of a degenerative brain disease. Specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of a degenerative brain disease comprising PAK4 (p21-activated kinase 4) or a PAK4 activator as an effective ingredient. In addition, the present invention relates to a pharmaceutical composition for the prevention or treatment of a degenerative brain disease comprising a CRTC1 expression enhancer or activator as an effective ingredient, a diagnostic kit for a degenerative brain disease comprising an agent for detecting CRTC1, and a method for screening a substance for the prevention or treatment of a degenerative brain disease, comprising (a) applying a candidate drug to brain tissue or brain cells containing CRTC1 gene or CRTC1 protein; (b) measuring the degree of phosphorylation in CRTC1; and (c) determining the candidate drug as a substance for the prevention or treatment of a degenerative brain disease when the measurement in step (b) indicates that the phosphorylation in CRTC1 is increased.

Aspects of the disclosure relate to compositions and methods for delivering a transgene (e.g., a transgene encoding one or more gene products) to a target cell (e.g., a brain cell). The disclosure is based, in part, on adeno-associated virus (AAV) capsid proteins comprising one or more amino acid substitutions, and methods of using the same for delivery of a transgene to tissues and cells of the central nervous system (e.g., brain cells).

The application provides a fusion protein, a gene, a recombinant vector, a recombinant cell, brain-targeting exosomes and application thereof, and relates to the field of drug treatment. The exosomes can be precisely targeted to a target site as a drug delivery carrier to play a therapeutic role of genes and chemical drugs. In the application, a gene sequence of a highly expressed NCAM gene in microglial cells, a segment of a simulation peptide NMP2, and a gene sequence of an exosome membrane protein Lamp2b are connected, an expression vector is constructed, and the expression vector is transfected into a packaging cell, so that the NCAM simulation peptide NMP2 is presented on the surface of the exosomes, the exosomes have the ability of targeting microglial cells, the exosomes can carry therapeutic drugs to pass through the blood-brain barrier and enter the lesion area in the brain, regulate the microenvironment, promote the clearance of A beta deposition, and can be used for the treatment of Alzheimer's disease.

This invention discloses the application of GRP94 protein as a drug delivery target in the construction of drug carriers for Parkinson's disease. GRP94 is highly upregulated on the cell membranes of dopaminergic neurons in the substantia nigra of Parkinson's disease cells, while its expression is extremely low on the surface of normal brain cells. The invention also discloses the application of GRP94 as a target in a targeted delivery system for anti-Parkinson's disease drugs. By targeting GRP94, the delivered anti-Parkinson's drug can efficiently penetrate the blood-brain barrier to reach the brain parenchyma, avoiding normal brain cells and specifically targeting dopaminergic neurons in the substantia nigra of Parkinson's disease cells, thus achieving targeted drug delivery for Parkinson's disease. This invention applies GRP94 as a target in the construction of drug carriers for Parkinson's disease and in the preparation of targeted delivery systems for anti-Parkinson's disease drugs. Compared to other target receptors that cross the blood-brain barrier for targeted brain delivery, targeting GRP94 more specifically targets dopaminergic neurons in the substantia nigra, avoiding drug accumulation and neurotoxicity in normal intracranial regions.

The invention relates to application of dyclonine and / or a derivative thereof in preparation of a medicine for treating post-resuscitation brain injury, and belongs to the technical field of medicines. The invention provides application of dyclonine and / or a derivative thereof in preparation of a medicine for treating brain injury after resuscitation. Cell experiments prove that the dyclonine can improve the effect of reducing the activity of neurons and microglial cells caused by rehydration and reoxygenation after hypoglycemia and hypoxia, so that the activity of brain cells is recovered. Meanwhile, animal experiments prove that dyclonine can improve brain nerve functions, the number of Nissl bodies, mitochondrial structures and ATP (adenosine triphosphate) levels of rats suffering from whole cerebral ischemia injury caused by cardiopulmonary resuscitation after cardiac arrest, so that the effect of improving brain injury caused by cardiopulmonary resuscitation after cardiac arrest is achieved. And the dyclonine also can protect the brain function.

There is provided a system and method for generating a mapping of local brain cell activity and connectivity. The method including: receiving brain imaging data from image captures of a brain; generating a binary segmentation map using a trained deep learning model, the deep learning model taking the brain imaging data as input; performing registration of the brain imaging data to a brain template; voxelizing the segmentation map and warping the voxelized segmentation map using deformations obtained during registration; determining group-wise heatmaps of neuronal density or cellular density from the voxelized and warped segmentation map; generating a map of clusters of between-group differences in neuronal density or cellular density from the group- wise heatmaps of the voxelized and warped segmentation map; and outputting the map of clusters as a representation of local brain cell activity and connectivity.

The application provides a brain function improving brain peptide hydrolysate drink composition and a preparation method and application thereof, relates to the technical fields of peptide drinks and medicines. The brain protease hydrolysate concentrate, walnut peptides and intestinal peptides are matched and the dosages thereof are preferably selected, so that the drink composition is fully absorbed, the nervous system is better activated, the excitability of brain cells is improved, the growth and lengthening of nerve synapses are stimulated, the repair of brain nerves is helped, the gastrointestinal movement is enhanced, the gastrointestinal mucosa is better protected, the burden of the spleen and stomach is reduced, and the application is especially suitable for patients with weak spleen and stomach.

The utility model relates to the technical field of ice caps, in particular to an anti-slip ice cap which comprises a cap body and a neck supporting protection pad, the cap body comprises a double-layer rubber layer, an annular opening is formed in the inner side of the double-layer rubber layer, an invisible zipper is fixed to the edge of the annular opening, a plurality of ice columns are arranged in an interlayer of the double-layer rubber layer, and the neck supporting protection pad is arranged in the interlayer of the double-layer rubber layer. A fixing piece is further fixed in the interlayer of the double-layer rubber layer, by arranging the fixing piece, each ice column is fixed in the placing hole of the heat preservation layer, ice blocks are prevented from sliding, moving and gathering to a certain position when a patient turns over or moves, chilblain is reduced, meanwhile, the brain oxygen consumption can be reduced, brain cells can be protected, and the patient can feel comfortable. And by arranging the containing bag, the double rubber layers and the sealing ring, the conditions of ice column melting and liquid leakage can be avoided, the ice column fusion time is shortened, and the comfort level of a patient is improved.

Provided herein are, inter alia, methods and compositions for transfecting a brain cell (e.g., neuron). The methods for transfecting a brain cell provided herein including embodiments thereof include, for example, transfecting the brain cell with a viral vector encoding a potassium-selective light-sensitive protein (e.g., kalium channelrhodopsin). Also provided herein are, inter alia, methods of modulating a neural network of brain cells (e.g., neurons) by activating a potassium-selective channelrhodopsin with light. The methods and compositions provided herein are, inter alia, useful for treating neurological or psychiatric diseases or disorders (e.g., epilepsies, Parkinson's disease, Alzheimer's, etc.).

[Problem] To provide amyloid β accumulation model cells. [Solution] A neurodegenerative disease model tissue and model animal, comprising brain cells derived from a non-human animal in which all or a part of a liver is replaced with human liver cells.

The invention relates to long-acting hydrogen release particles for targeted anchoring of apoplexy inflammation blood vessels as well as a preparation method and application of the long-acting hydrogen release particles. The preparation method comprises the following steps: 1.1) completely and uniformly mixing ZrSiraw material powder, a dispersing agent and a solvent in a mass ratio of 100: (50-1000): (10-10000); 1.2) transferring the mixture into a ball mill for ball milling at a ball milling speed of 200-1000 revolutions per minute for 1-7 days; 1.3) carrying out graded centrifugation on the ball-milled solution, and collecting particles with the particle size of 50-200 nanometers; and 1.4) washing, centrifuging again to obtain the required ZrSi nano-particles, dispersing the ZrSi nano-particles into a solvent, and storing in a nitrogen environment. In cerebral apoplexy, the nanoparticles anchored on inflammatory blood vessels do not need to pass through the blood brain barrier, so that potential safety risks caused by the nanoparticles to brain parenchyma are avoided. And moreover, Hs can be generated in local hydrolysis, and then the Hs pass through the blood brain barrier, so that safe and effective brain cell protection is realized. And hydrogen can be continuously released, so that continuous treatment is realized, and accumulation of nanoparticles in brain parenchyma is avoided.

The invention provides a high-resolution microelectrode neuron stimulation system. The high-resolution microelectrode neuron stimulation system comprises at least two stimulation electrodes, a first control module and a second control module, the peripheries of the stimulating electrodes are connected to form a stimulating area; the first control module is provided with a first signal source and at least two first switches. The first signal source provides a first current with a first frequency. The second control module is provided with a second signal source and at least two second switches, the second signal source provides a second current with a second frequency, the current intensity of any two electrodes can be controlled through the structure, brain cell tissue at a target position in a stimulation area is selectively stimulated, and the stimulation efficiency is improved. According to the invention, the electrode setting complexity and the setting cost can be reduced, and the effect of high-precision neuron stimulation is achieved.

The present invention provides a device for treating Alzheimer's disease comprising elements for repairing the mitochondrial network structure of brain cells in a patient with Alzheimer's disease. The device disclosed by the invention can be used for improving cognitive impairment of a patient through intervention of a plurality of targets aiming at various pathogenic mechanisms of the Alzheimer's disease. After the composition is applied to a patient, not only can the mitochondrial network structure of brain cells in the patient be repaired, but also the concentration of A beta protein (reduced by 25%), the concentration of p-tau protein (reduced by 40%) and the concentration of caspase-3 protein (reduced by 36%) in the brain can be reduced, and gene expression related to development of the Alzheimer's disease can be partially recovered. In addition, the device performs treatment through gamma NIR light, and has the advantages of being non-invasive and high in safety.

The invention relates to the technical field of plastic brain toxicity detection, and discloses a plastic brain toxicity detection method, which comprises the following steps: giving a preset number of food particles and water to mice in a target environment, and randomly dividing the mice into groups; after the mice are weighed, MNP with a preset concentration is administered to the experimental group regularly every day, normal saline is administered to the control group, 3D behavioral recording is conducted on the mice after several days of continuous administration, and behavioral analysis is conducted according to the recording result; and after behavioral analysis, performing injection anesthesia on the mice in each group, sampling brain tissues of the mice in each group, and performing brain cell analysis based on the brain tissues of the mice so as to detect the plastic brain toxicity. The toxicity of micro-plastic or nano-plastic can be efficiently and accurately detected through systematic experiment steps.

The application provides a construction method of a zebrafish model of diabetic cerebral hemorrhage sequelae for high-throughput drug screening, and belongs to the technical field of biotechnology.The first zebrafish model capable of comprehensively simulating the complex pathological phenotypes of clinical diabetic cerebral hemorrhage sequelae is successfully constructed, and the blank of the research model in the field is filled.The pathological changes of the model are highly consistent with the symptoms of the patients with clinical diabetic cerebral hemorrhage sequelae, such as glucose metabolism disorder, pancreatic beta cell damage, cerebral vascular injury and hemorrhage, brain cell apoptosis, inflammatory reaction and behavior abnormality, and the limitation that the existing single disease model cannot simulate the synergistic pathogenesis of diabetes and cerebral hemorrhage is overcome, so that a reliable experimental animal model is provided for high-throughput screening of active ingredients against the disease.